See this ref. for explanation of "mature":
http://216.239.59.104/search?q=cache:XdIoa29XjrMJ:www.medica... Among the patients receiving combination therapy:
-- The median TTP was 282 days (9.3 months), versus 197 days (6.5 months) for patients randomized to receive VELCADE alone (p = 0.000004).
-- The hazard ratio for VELCADE monotherapy versus the combination therapy was 1.82 (95 percent confidence interval, 1.41, 2.35). (A hazard ratio greater than one indicates an advantage for the combination.)
-- The overall survival analysis showed a trend favoring the combination therapy group, but the results were not mature (i.e., too few events of death) and had not reached statistical significance (p=0.113) at the time of the interim analysis.
peer agreement (net): +3